NYMC Faculty Publications

Outcome of Transplantation for Acute Lymphoblastic Leukemia in Children With Down Syndrome

Author Type(s)

Faculty

DOI

10.1002/pbc.24918

Journal Title

Pediatric Blood & Cancer

First Page

1126

Last Page

1128

Document Type

Article

Publication Date

6-1-2014

Department

Pediatrics

Keywords

Adolescent, Adult, Allografts, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow Transplantation, Child, Child, Preschool, Combined Modality Therapy, Cyclosporine, Disease-Free Survival, Down Syndrome, Genetic Predisposition to Disease, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Infant, Kaplan-Meier Estimate, Living Donors, Myeloablative Agonists, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Registries, Remission Induction, Retrospective Studies, Salvage Therapy, Tacrolimus, Transplantation Conditioning, Treatment Outcome, Whole-Body Irradiation

Disciplines

Medicine and Health Sciences

Abstract

We report on 27 patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) who received allogeneic hematopoietic cell transplantation (HCT) between 2000 and 2009. Seventy-eight percent of patients received myeloablative conditioning and 52% underwent transplantation in second remission. Disease-free survival (DFS) was 24% at a median of 3 years. Post-transplant leukemic relapse was more frequent than expected for children with DS-ALL (54%) than for non-DS ALL. These data suggest leukemic relapse rather than transplant toxicity is the most important cause of treatment failure. Advancements in leukemia control are especially needed for improvement in HCT outcomes for DS-ALL.

Link to Full Text

Share

COinS